As of early 2026, market research data from IQVIA indicates that GLP-1 receptor agonist prescriptions in the United States are growing at approximately 35% year-over-year, with an estimated 9 million active patients on GLP-1 therapies, a figure projected to exceed 30 million by 2030
Patients with prior pancreatitis or severe gastrointestinal ailments should explore alternative treatments with their provider
As the effect wears off, your body's metabolism will return to normal
Liposomal Berberine for Better Absorption: Our berberine is delivered using advanced liposomal technology, designed to help the body absorb and utilize the ingredient more effectively for everyday nutritional support
The NHS supports the use of validated home blood pressure monitors, which allow patients to track their readings between clinic appointments
If you're already on a GLP-1 for diabetes or weight management and you're noticing endo improvements, document them and share with your doctor